News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

GTx, Inc. (GTXI) Release: Preliminary Findings From The Phase 2 Clinical Trial Of Gtx-758 In Men With Castration Resistant Prostate Cancer To Be Presented At American Society of Clinical Oncology Genitourinary Cancer Symposium


1/29/2014 9:14:01 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

MEMPHIS, Tenn.--(BUSINESS WIRE)--GTx, Inc. (NASDAQ: GTXI) announced today that Dr. Evan Yu, Associate Professor of Medicine and Oncology at the University of Washington School of Medicine and Clinical Trials Director, Genitourinary Oncology Clinical Trials Core, Seattle Cancer Care Alliance, will present preliminary findings from the Company’s Phase 2 clinical trial evaluating GTx-758 (Capesaris®), an oral estrogen receptor alpha agonist, in men with metastatic castrate resistant prostate cancer (CRPC) at the 2014 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancer Symposium in San Francisco, CA on Thursday, January 30, 2014.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES